Gilead Sciences, Inc (NASDAQ : GILD) is one of the favored stock by institutional shareholders which hold 85% of the company's stock. The company has displayed a variety of stock movement recently, moving by both -0.04% and -0.84%. Despite this fluctuations, the stock has managed to exceed market returns. Current investor trends indicate interest in the company, however, Q1 2024 earnings showed mixed results falling short of analyst EPS estimates. Despite a dip in broader markets, GILD stock has managed to maintain growth. This is particularly noted with GILD's rise by 19% over the past month. Q1 2024 also saw a loss, but beat revenue estimates. The company's dividend has been reported to increase to $0.77, with the HBV drug Vemlidy receiving European Approval. Gilead also recently announced an exclusive license agreement with Xilio for an IL-12 program, showing progression in its product pipeline.
Gilead Sciences GILD News Analytics from Wed, 27 Sep 2023 07:00:00 GMT to Sun, 19 May 2024 00:44:05 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor -4
